Mechanism and clinical application of sodium-glucose co-transportor 2 inhibitors:research advances
10.13220/j.cnki.jipr.2017.09.002
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂作用机制及临床应用研究进展
- Author:
Song-Tao DONG
1
;
Zhan-Jun DONG
Author Information
1. 中国医科大学药学院
- Keywords:
type 2 diabetes mellitus;
sodium-glucose co-transportor 2,inhibitors;
mechanism of action;
clinical medication
- From:
Journal of International Pharmaceutical Research
2017;44(9):828-834
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-glucose co-transportor 2(SGLT2)exerts an important role in the reabsorption of renal glucose,and SGLT2 inhibitors could reduce the blood glucose level in type 2 diabetes mellitus patients by decreasing renal glucose reabsorption and in-creasing urine glucose excretion. This paper briefly reviews the renal regulation of glucose homeostasis and the regulatory mechanism of SGLT2 inhibitors,then summarized the administration,clinical pharmacology,adverse reaction and other aspect of clinical applica-tion of three most representive SGLT2 inhibitors:dapagliflozin,canagliflozin and empagliflozin,in hope of providing reference for clinical use of SGLT2 inhibitors in the future.
